Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) is taken as a once-weekly subcutaneous injection, using a pre-filled pen injected into the abdomen, thigh, or upper arm. You rotate the site each week, and the dose starts low before your prescriber steps it up gradually over several months. As a prescription-only medicine, a clinician must assess your suitability before treatment begins — no two patients' journeys look identical.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: your pen has arrived, you've read the leaflet, and you're standing in the bathroom wondering whether this is going to be as involved as you feared. In practice, it usually isn't. Wegovy's pre-filled pen is designed for self-administration. You press it against a pinched fold of skin (abdomen, outer thigh, or upper arm) hold it in place, and the injection is over in seconds. The needle is short and fine; most people describe the sensation as minimal.
What matters more than the technique is where you inject. You rotate the site every week, which gives the tissue time to recover and helps avoid localised reactions. You can use the same general area (the stomach, say) but shift the exact spot a few centimetres each time. A common question our prescribers hear is whether the abdomen is the only sensible choice; it isn't, though many people find it the easiest to reach. The step-by-step guide to taking Wegovy on this site covers the preparation in more detail.
The pen itself is single-use and pre-set, there's nothing to draw up or dial. Once you've used it, it goes into a sharps container. The NHS semaglutide page has patient-level guidance on the injection technique if you want a second read before your first dose.
Treatment begins at 0.25 mg weekly. That dose exists to settle your digestive system, not to produce meaningful weight loss, the therapeutic work happens at higher doses. After four weeks, your prescriber moves you to 0.5 mg, then 1.0 mg, then 1.7 mg, and finally the 2.4 mg maintenance dose, again spending roughly four weeks at each step. That's a minimum of around five months to reach maintenance, and your prescriber may slow the pace if side effects are significant.
The newer Wegovy 7.2 mg pen (approved by the MHRA in April 2026 as a single-dose weekly injection for adults with a BMI of 30 or above) extends the maximum dose further for those who tolerate and need it. The starting dose remains 0.25 mg regardless; nobody begins at 7.2 mg. Whether a higher maintenance dose is appropriate is a clinical decision made over time, not something set at the first consultation.
The slow climb is also the reason that questions about how often Wegovy is taken and confirming the weekly schedule come up so often, once-weekly, same day each week, is the answer, and consistency matters more than the exact time of day.
The side-effect profile of Wegovy is led by the gut. Nausea is the most commonly reported effect, typically most noticeable in the first days after a dose increase and often settling within a week or two as your body adjusts. Vomiting, loose stools, constipation, indigestion and fatigue appear in the clinical data too. For most people these are manageable; eating smaller portions, avoiding rich or fatty meals, and staying well hydrated all tend to help. If symptoms feel severe or prolonged, your prescriber needs to know.
One thing that matters more than people expect: Wegovy pens must be kept refrigerated between 2°C and 8°C. Many patients keep them in the fridge door. If you need to travel with your pen, or if it's been left out, check the Patient Information Leaflet for the exact temperature window, we don't quote it here because that's information your leaflet carries precisely. Details on storing Wegovy safely are worth reading before your first pen arrives.
It's also worth knowing that Wegovy is a long-term treatment. The question of whether Wegovy is taken for life comes up regularly; the honest answer is that clinical evidence suggests weight tends to return if treatment stops, and ongoing use should be reviewed regularly with your prescriber. That review is built into how nume works, every repeat order is clinically re-assessed, not auto-renewed. For context on what Wegovy costs privately in the UK, that page explains what a legitimate price includes and what to watch for.
If you'd like to understand semaglutide more broadly (how it works as a medicine, its licensed indications, and how it compares to other options) the semaglutide overview is a good starting point, or you can explore Wegovy's full profile here. When you're ready to find out whether it's clinically suitable for you, speak to our prescribers, a GPhC-registered Independent Prescriber reads every consultation the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.